Oxford Biomedica (OXB)

Sector:

Pharma and Biotech

Index:

FTSE Small Cap

NULL
   
  • Closing Price Chg:
      18.00p
  • 52 Week High: NULL
  • 52 Week Low: 233.00p
  • Currency: UK Pounds
  • Shares Issued: 106.14m
  • Volume: 0
  • RiskGrade: 125
  • Beta: 0.02

Financial Analysis

Select chart: EPS | Dividend | Revenue

Key Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-20 87.73 (6.57) (7.81)p n/a n/a n/a n/a 0.0%
31-Dec-21 142.80 19.88 22.77p 54.0 n/a n/a n/a 0.0%
31-Dec-22 139.99 (45.98) (41.29)p n/a n/a n/a n/a 0.0%
31-Dec-23 89.54 (188.53) (163.11)p n/a n/a n/a n/a 0.0%
31-Dec-24 128.80 (47.26) (41.75)p n/a n/a n/a n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-25 161.82 (23.48) (31.21)p n/a n/a n/a n/a 0.0%
31-Dec-26 208.03 2.78 (13.20)p n/a n/a n/a n/a 0.0%
31-Dec-27 244.81 19.58 5.88p 78.0 n/a n/a n/a 0.0%

Copyright © 2025 FactSet Research Systems Inc. All rights reserved.

Price / Earnings Data

5 Yr High 5 Yr Low 5 Yr Avg Curr / Avg
Latest 54.02 n/a n/a 0

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

IFRS Changes - Find Out More

Find out about IFRS and how this affects the financial infomation for all UK companies.

OXB Market Data

Currency UK Pounds
Share Price NULL
Closing Price Change 18.00p
% Change 0.00 %
52 Week High NULL
52 Week Low 233.00p
Volume 0
Shares Issued 106.14m
Beta 0.02
RiskGrade 125

OXB Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
32.44% below the market average32.44% below the market average32.44% below the market average32.44% below the market average32.44% below the market average
31.71% above the sector average31.71% above the sector average31.71% above the sector average31.71% above the sector average31.71% above the sector average
Price Trend
53.87% above the market average53.87% above the market average53.87% above the market average53.87% above the market average53.87% above the market average
77.78% above the sector average77.78% above the sector average77.78% above the sector average77.78% above the sector average77.78% above the sector average
Income Not Available
Growth
4.65% above the market average4.65% above the market average4.65% above the market average4.65% above the market average4.65% above the market average
20% below the sector average20% below the sector average20% below the sector average20% below the sector average20% below the sector average

What The Brokers Say

Strong Buy 4
Buy 2
Neutral 4
Sell 0
Strong Sell 0
Total 10
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

OXB Dividends

No dividends found

Trades for --2025

Time Volume / Share Price
0 @ 0.000p

OXB Key Personnel

Chair Roch Doliveux
CEO Frank Mathias
CFO Lucinda (Lucy) Crabtree

Top of Page